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The kidneys play a major role in the regulation of glucose in
humans, reabsorbing 99% of the plasma glucose that filters
through the renal glomeruli tubules. The glucose transporter,
SGLT2, which is found primarily in the S1 segment of the
proximal renal tubule, is essential to this process, accounting
for 90% of the glucose reabsorption in the kidney. Evidence
has suggested that selective inhibition of SGLT2 induces
glucosuria in a dose-dependent manner and may have
beneficial effects on glucose regulation in individuals with
type II diabetes. Preclinical data with SGLT2 inhibitors, such
as dapagliflozin and sergliflozin, show that these compounds
are highly selective inhibitors for SGLT2, have beneficial
effects on the glucose utilization rate, and reduce
hyperglycemia while having no hypoglycemic adverse
effects. Clinical research remains to be carried out on the
long-term effects of glucosuria and other potential effects of
this class of drug. Nonetheless, these compounds represent a
very promising approach for the treatment of diabetes.
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The kidney plays a pivotal role in the regulation of glucose
reabsorption, and by extension has a major part in
maintaining the overall metabolic balance of the body. In
healthy humans, more than 99% of the plasma glucose that
filters through the renal glomerulus is reabsorbed. Transport
of glucose across cell membranes is accomplished by two
gene families: the facilitative glucose transporters – the
GLUTs – and by an active sodium-dependent transport
process mediated by the sodium–glucose co-transporters
(SGLTs).1 The latter process allows glucose to be accumulated
in cells against the concentration gradient.
The SGLTs are a large family of membrane proteins
involved in the transport of glucose, amino acids, vitamins,
osmolytes, and some ions across the brush-border membrane
of the intestinal epithelium and of the proximal renal
tubules.1 The low-capacity, high-affinity Na/glucose co-
transporter, SGLT1, is mainly expressed in the gastrointest-
inal tract, whereas the high-capacity, low-affinity transporter,
SGLT2, is expressed primarily in the kidney.1 In the intestine,
SGLT1 performs an important function in the absorption of
glucose.2 SGLT3 is widely expressed throughout the body and
can be found in the skeletal muscle and the enteric nervous
system; however, it is not a glucose transporter, but appears
to have a role as a glucose sensor.2 Although there are other
members of the SGLT family, including SGLT4, 5, and 6, little
is known about the function of these isoforms in humans.2,3
SGLT2 AND GLUCOSE REABSORPTION IN THE PROXIMAL
RENAL TUBULE
Although SGLT1 plays a primary role in absorption of
glucose in the intestine, in the kidney SGLT2 is the primary
factor. Accounting for 90% of glucose reabsorption in the
kidney, SGLT2 is found primarily in the brush-border
membrane of the S1 segment of the proximal renal tubule.
SGLT1 is located more distally in the S3 segment of the
proximal tubule and accounts for only 10% of renal glucose
reabsorption.4 Two basolateral membrane glucose transpor-
ters facilitate transcellular glucose transport – the low-affinity
GLUT2, which works in conjunction with SGLT2 in the S1
segment of the renal tubule, and the high-affinity GLUT1,
which works with SGLT1 in the S3 segment.5
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Although the filtered load of glucose isB180 g/day, in the
normal kidney only B500 mg of glucose is excreted in the
urine over a 24-h period. The remaining is reabsorbed, as it
flows from the glomerulus through the proximal tubule,
passing from S1 to S3, where first SGLT2 and then SGLT1
transport glucose from the glomerular filtrate in the tubule
lumen into the tubule cells. Once glucose enters the cells,
GLUT2 and GLUT1 facilitate exit from the cell across the
basolateral membrane into the interstitial fluid,6 and from
there it is picked up by the peritubular capillary. The
efficiency of the transport system is such that as the filtrate
moves from S1 to S2 and to S3, the glucose concentration
decreases dramatically, and only a few millimeters away from
the glomerulus, all of the glucose gets reabsorbed into the
bloodstream. The thermodynamic machinery of the SGLTs
couples glucose and sodium transport into the proximal
tubule epithelial cells (Figure 1).
Gene mutation of SGLT1 has serious consequences for
afflicted individuals, who experience glucose–galactose ma-
labsorption, frequent watery diarrhea, and dehydration.7
However, these individuals have little or no glucosuria.
Approximately 21 different gene mutations have been
described for SGLT2.8 Those who have SGLT2 mutations
have persistent renal glucosuria, with glucose excretion
of up to 160 g/day. Although no other complications are
known to be associated with mutations of this gene, it is a
rare benign genetic condition not well studied.8 The
observation that in contrast to SGLT2 mutations, SGLT1
mutations are accompanied by little or no glucosuria
supports a limited role for SGLT1 in the kidney and a much
larger one for SGLT2.7
Phlorizin, a nonselective SGLT inhibitor, has been used to
explore the role of SGLT activity in glucose regulation.
However, it has significant limitations, both as an investiga-
tive tool and as a potential pharmacological treatment for
diabetes. First, it is a potent inhibitor of both SGLT1 and
SGLT2,9 and thus it is not possible to use phlorizin to
distinguish SGLT1 and SGLT2 activities. Second, oral
phlorizin causes malabsorption of glucose and diarrhea
(analogous to the inherited condition due to SGLT muta-
tions). The development of the selective inhibitors of SGLT2,
for example, sergliflozin and dapagliflozin, has helped
elucidate the role of this transporter in the kidney.
SGLT2 AND DIABETES MELLITUS
There is a transport maximum (Tm) for glucose; in
hyperglycemic individuals, when glucose levels approach
400 mg glucose per 100 ml plasma, the Tm for glucose of
375 mg/min is exceeded. Consequently, the patient begins to
excrete large amounts of glucose in the urine even though the
renal tubules continue to function normally.
The issue of gene expression and the possibility of SGLT
adaptation to chronic hyperglycemia is an area rich for
investigation. Studies in animal models of diabetes show that
small amounts of adaptation do occur, and there appears to
be a twofold increase in the expression of SGLT2 mRNA. The
results of a recent study in rats with experimental diabetes10
suggest that plasma glucose concentration is an important
regulator of hepatocyte nuclear factor-1a transcription factor
expression and activity.10 Hepatocyte nuclear factor-1a
directly controls SGLT2 gene expression in humans and
rats.10 Induction of diabetes in rats increased mRNA
expression of both SGLT2 and hepatocyte nuclear factor-1a
in the renal cortex. A 6-day treatment with insulin or with
phlorizin improved glycemic control and reduced the
expression of SGLT2 and hepatocyte nuclear factor-1a to
near normal levels.10 The authors of this study concluded
that these findings suggest that enhanced SGLT2 expression
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Figure 1 | Glucose reabsorption from the glomerular filtrate through a proximal tubule epithelial cell into the blood. Modified with
permission from Wright et al.3
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may contribute to the development of diabetic renal tubular
and glomerular disease.10
CURRENT THERAPIES FOR HYPERGLYCEMIA IN TYPE II
DIABETES AND UNMET NEEDS
Current non-insulin-based therapies for type II diabetes
mellitus (DM2) include sulfonylurea-related secretagogues,
metformin, the a-glucosidase inhibitors, incretin mimetics,
DPP-4 inhibitors, and thiazolidinediones.11–13 The a-gluco-
sidase inhibitors inhibit carbohydrate digestion in the gut,
whereas incretin mimetics slow gastric emptying, increase
insulin secretion, and decrease glucagon secretion. The DPP-
4 inhibitors also increase insulin secretion and decrease
glucagon secretion, whereas the secretagogues simply stimu-
late secretion of insulin. Metformin and thiazolidinediones
enhance insulin action in the liver and its periphery,
respectively, and thereby increase glucose metabolism and
suppress glucose production. Thiazolidinedione therapy also
increases glucose intake and decreases free fatty acid
output.11–13
Current therapies are associated with a number of
important adverse events that can affect adherence to therapy
or the health of the patient. Metformin is associated with
gastrointestinal effects such as nausea and diarrhea, which
occur in up to 50% of patients, and rarely, with lactic
acidosis, and, importantly, is contraindicated in patients with
moderate-to-severe renal disease.14 The sulfonylureas and
meglitinides are associated with hypoglycemia, weight gain,
and hyperinsulinemia; and weight gain and edema can occur
with the use of thiazolidinediones. a-Glucosidase inhibitors
may cause malabsorption symptoms in patients,14 whereas
the incretin mimetics have gastrointestinal effects such as
nausea, vomiting, and diarrhea.15–18
Given the progressive nature of DM2, most patients
eventually require combinations of oral antidiabetic medica-
tions.14 The United Kingdom Prospective Diabetes Study
(UKPDS) found that after 3 years, only 50% of patients were
adequately controlled on a single medication, and that after 9
years, only 25% were controlled on monotherapy.19 The
reasons for the difficulty in achieving glycemic goals are
complex. Although the reluctance of medical professionals
and patients to intensify treatment may contribute, it seems
likely that the progression of the underlying disease process,
together with dose-limiting side effects of treatment,
contributes to the poor glycemic control that is common in
DM2. The recent ACCORD study showed an increase in
mortality when attempts at achieving normoglycemia were
made with multiple combinations of these drugs.20 Thus,
better and safer therapy is needed to prevent the complica-
tions of diabetes.
SGLT INHIBITION: PRECLINICAL DATA
The classic inhibitor of sodium-dependent glucose transport
is phlorizin, and it is well known that oral delivery produces
glucosuria in both animals and humans, inhibits glucose
absorption, and produces diarrhea.21 This plant glucoside is a
potent competitive inhibitor of SGLT1 and SGLT2, with sub-
micromolar Kis, but is only a poor inhibitor of facilitated
glucose transporters (GLUTs), Ki40.5 mM.
9 Phlorizin treat-
ment of male diabetic Wistar rats was recently compared with
insulin and a placebo.10 Insulin injection resulted in a 4-h
decreased plasma glucose, which remained low at 12 h.
Phlorizin produced a similar significant decrease in plasma
glucose (Po0.001 for both phlorizin and insulin at 4 h as
compared with placebo). However, insulin-treated rats
experienced hyperinsulinemia, as expected, but insulin levels
remained low in the phlorizin-treated rats. Insulin treatment
resulted in rapid weight gain, and 4- and 6-day-treated rats
were 16 and 20% heavier, respectively, than placebo-treated
rats (Po0.05).10 In contrast, phlorizin-treated rats did not
experience change in weight or insulin concentration. Insulin
treatment lowered plasma glucose by 24% after 1 day of
treatment (Po0.01) and 60% after a 6-day regimen
(Po0.001), whereas phlorizin treatment resulted in a 56%
decrease in plasma glucose after 1 day and a 55% decrease on
days 4 and 6 (Po0.001).10
Over 21 SGLT inhibitors are in the drug pipeline, and
most exploit the chemical space of phlorizin. One of the first
was the oral prodrug T-1095.22 The prodrug did not inhibit
intestinal glucose absorption, but its metabolite T-1095A
effectively blocked renal glucose reabsorption. The usefulness
of this SGLT inhibitor was explored in a study on diabetic
and normoglycemic male mice.23 It was proposed that the
higher SGLT activity in diabetic mice than in non-diabetic
mice would provide the rationale for the use of an SGLT
inhibitor as DM2 therapy.23 A single oral administration of
T-1095 to diabetic mice resulted in a dose-dependent
reduction in blood glucose levels and an increase in glucose
excretion in the urine. Blood glucose levels of non-diabetic
control mice were only slightly affected by the compound.
Chronic administration of T-1095 resulted in decreases in
both blood glucose and HbA1c levels in diabetic mice, as well
as 2.5-fold increases in pancreatic levels of insulin (Figure 2).
In addition, progression of diabetic nephropathy was
prevented, with suppression of both development of
albuminuria and expansion of the glomerular mesangial
area.23 This study provided a proof of principle of targeting
renal SGLTs in diabetics.
SELECTIVE SGLT2 INHIBITION
Selective SGLT2 inhibitors offer the potential to affect only
the kidney, allowing excretion of glucose and creation of a
negative energy balance without a potential gastrointestinal
side effect profile. Two SGLT2 inhibitors currently under
investigation are dapagliflozin, a C-aryl glucoside, and
sergliflozin, an O-glucoside.24,25
Dapagliflozin has a 1200-fold selectivity for SGLT2 over
SGLT1 as compared with phlorizin’s 10-fold selectivity.24 In
vitro studies indicate that the inhibitory potencies against rat
SGLT2 and human SGLT2 are comparable.24 When adminis-
tered to streptozotocin-induced diabetic rats, dapagliflozin
resulted in anB55% reduction in blood glucose as compared
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with controls at 5 h after a single dose.24 Lower doses
produced less glucose lowering in diabetic rats.
A recent study26 provides additional evidence to support
the potential of SGLT2 inhibitors to lower blood glucose. The
investigators used cell-based assays in human SGLT1- and
SGLT2-cloned cell lines to measure glucose analog uptake
and assess dapagliflozin’s ability to inhibit sodium-dependent
and facilitative glucose transport activity. In addition, acute
and multi-dose studies were conducted in normal and
Zucker diabetic fatty rats to evaluate the effect of dapagli-
flozin on fed and fasting plasma glucose levels. Finally, a
hyperinsulinemic euglycemic clamp study was performed to
explore the compound’s ability to improve glucose utilization
after multi-dose treatment.
The in vitro study showed that dapagliflozin was
approximately 30-fold more potent than phlorizin against
human SGLT2 and approximately 4-fold less potent against
human SGLT1. Dapagliflozin did not significantly inhibit
facilitative glucose transport in human adipocytes.26 The in
vivo studies showed that dapagliflozin induced significant,
dose-dependent glucosuria in both normal and Zucker
diabetic fatty rats, enhanced glucose tolerance in normal
rats, and decreased hyperglycemia in Zucker diabetic fatty
rats after single oral doses ranging from 0.1 to 1.0 mg/kg.26
Two-week treatment with once-daily dapagliflozin lowered
fasting and fed glucose levels significantly at doses ranging
from 0.1 to 1.0 mg/kg (Figure 3). No body weight changes
compared with vehicle-treated rats were observed. Further-
more, use of the compound caused a significant increase in
the glucose utilization rate, which was accompanied by a
significant reduction in glucose production and enhanced
liver insulin sensitivity.26 Hypoglycemia was not observed in
any of the groups during the course of the acute and chronic
studies.26
Sergliflozin-A is a highly potent and selective inhibitor of
SGLT2. In rats, mice, and dogs, oral administration of
sergliflozin results in increased urinary glucose excretion in a
dose-dependent manner. It also significantly lowers plasma
glucose in a dose-dependent manner when administered to
streptozotocin-induced diabetic rats without stimulating
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Figure 2 | Effects of chronic T-1095 treatment on blood glucose, HbA1C, plasma insulin, and body weight. Effects of chronic T-1095
treatment on blood glucose (a), plasma insulin (b), HbA1C (c), and body weight (d) in C57BL/KsJ-db/db (db/db) mice, a genetic animal
model of obese type 2 diabetes. T-1095 (0.03 and 0.10% in diet) was given for 12 weeks. Blood glucose, HbA1C, plasma insulin levels, and
body weight were monitored periodically. Symbols represent mean values and vertical lines show s.e. mean (n¼ 8). ##Po0.01 versus
db/þm mice. *Po0.05, **Po0.01 versus control. Reprinted with permission from Arakawa et al.23
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insulin secretion.25 It does not significantly alter normal
glucose levels in 6-h fasted rats, however, suggesting that the
risk of hypoglycemia is low. Unlike phlorizin, which is
hydrolyzed to phloretin, sergliflozin does not appear to have
any effect on GLUT1 at pharmacological concentrations.25
Nor does sergliflozin have an effect on urinary electrolyte
excretion except for a temporary osmotic diuresis that occurs
only at the highest dose.25
CONCLUSIONS
High plasma glucose levels appear to have a deleterious effect
on the kidneys in those with diabetes. SGLT2 plays an
important role in reabsorption of glucose in the proximal
renal tubule. Animal studies suggest that selective inhibition
of SGLT2 reduces plasma glucose levels without inducing
insulin secretion, hypoglycemia, or weight gain. Two SGLT2
inhibitors, dapagliflozin and sergliflozin, are currently under
investigation as possible therapies in DM2, with promising
animal data. However, much remains to be explored with
these compounds. The long-term effects of glucosuria need
to be determined. In addition, these drugs are lipid-soluble,
and therefore will cross the blood–brain barrier. The SGLTs
are found within the hypothalamus, where they sense and
respond to changes in glucose concentrations.27 It is therefore
critical that potential effects such as these are explored to
determine the safety of these compounds.
It is clear, however, from the low rates of glucose control
in the diabetic population that there is a need for an
alternative approach to management of diabetes. Targeting
the SGLT2 transporter in the kidney seems to be a very
promising approach for the treatment of DM2.
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